The Rgr oncogene induces tumorigenesis in transgenic mice.

TitleThe Rgr oncogene induces tumorigenesis in transgenic mice.
Publication TypeJournal Article
Year of Publication2004
AuthorsJiménez M, de Castro IPérez, Benet M, García JF, Inghirami G, Pellicer A
JournalCancer Res
Volume64
Issue17
Pagination6041-9
Date Published2004 Sep 01
ISSN0008-5472
KeywordsAnimals, CD4 Antigens, Cell Cycle Proteins, Cell Transformation, Neoplastic, Cyclin-Dependent Kinase Inhibitor p15, Disease Progression, Female, Lymphoma, T-Cell, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, NIH 3T3 Cells, ral Guanine Nucleotide Exchange Factor, Transfection, Tumor Suppressor Proteins
Abstract

To study the oncogenic potential of Rgr in vivo, we have generated several transgenic Rgr mouse lines, which express the oncogene under the control of different promoters. These studies revealed that Rgr expression leads to the generation of various pathological alterations, including fibrosarcomas, when its transgenic expression is restricted to nonlymphoid tissues. Moreover, the overall incidence and latency of fibrosarcomas were substantially increased and shortened, respectively, in a p15INK4b-defective background. More importantly, we also have demonstrated that Rgr expression in thymocytes of transgenic mice induces severe alterations in the development of the thymocytes, which eventually lead to a high incidence of thymic lymphomas. This study demonstrates that oncogenic Rgr can induce expression of p15INK4b and, more importantly, that both Rgr and p15INK4b cooperate in the malignant phenotype in vivo. These findings provide new insights into the tumorigenic role of Rgr as a potent oncogene and show that p15INK4b can act as a tumor suppressor gene.

DOI10.1158/0008-5472.CAN-03-3389
Alternate JournalCancer Res
PubMed ID15342385
Grant ListCA50434 / CA / NCI NIH HHS / United States
CA90773 / CA / NCI NIH HHS / United States
Related Faculty: 
Giorgio Inghirami, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700